- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03591237
MBCT for Cancer Patients in Follow-Up
May 24, 2019 updated by: University of Aarhus
Mindfulness-based Cognitive Therapy for Pain in Cancer Patients After Primary Treatment: An Open Implementation Trial
The objectives of the present study are: 1) to executing the practical implementation in an oncology department of MBCT for patients who have completed their primary treatment and experience significant cancer- and cancer-treatment-related pain, 2) to evaluate effects on pain and well-being, 3) to explore patient satisfaction with the intervention offered, and 4) to explore possible organizational and individual physical, mental and socio-economic barriers for implementation in relation to drop-outs.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
International research shows that untreated or under treated pain among cancer patients after completion of therapy is a common problem with substantial negative impact on the patients' quality of life and mental and physical function.These challenges have increased interest in psychological pain therapy and among the available methods of psychological intervention, mindfulness-based interventions (MBI) are of particular interest.
MBI appears to be particularly relevant for pain, as mindfulness focuses, through different meditation exercises, on concentrating attention on here-and-now experiences and supporting new ways of addressing physical sensations and emotional discomfort, characterized by greater acceptance and openness.
MBI has been shown effective in treatment of nonmalignant chronic pain. .
Patients seen by all four diagnosis teams at the Oncology Department at AUH are screened for pain (0-10 NRS) in connection with their final consultation with the oncologist.
Patients with a pain score of ≥ 4 on one or more of the four pain dimensions questions receive a folder describing MBCT and the treatment plan and are encouraged to contact the MBCT team for more information and scheduling of an interview.
If the patient, after initial information either by phone or after the first interview decline the offer to participate, but are willing to be contacted for the purpose of gathering more information about their reasons for not participating, we will send them a brief questionnaire concerning their pain and their reasons for choosing to decline the offer, to complete online.
They are also asked to give their permission to collect the same information after three months.
All data are collected and registered with REDCap, a high data security project administration system administered by Aarhus University's Clinical Trial Unit.
The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
The participants will be asked to record their home training to allow assessment of their adherence to the intervention.
The program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including somewhat shorter sessions, shorter yoga exercises, and the omission of the all-day session.
The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
The aim of the present project is to evaluate the practical implementation of MBCT, with focus on: 1) the observed effects on pain (primary outcome parameter), 2) effects on quality-of-life (QoL) and on other cancer and cancer-treatment-related late effects associated with pain (secondary outcome parameter), 3) possible barriers for continued participation in the program (drop-out), 4) patient experience and satisfaction with the intervention and its organizational/practical implementation, 5) staff's experience of screening procedure and implementation, and 6) collection of data for use in the evaluation of effects, costs, and savings.
For use in the evaluation, the patients complete questionnaires prior to the first session (T1), immediately after the last session (T2), and at a six-month follow-up (T3).
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ingeborg Farver-Vestergaard, Ph.D.
- Phone Number: +4587166154
- Email: ifarver@psy.au.dk
Study Contact Backup
- Name: Maja Johannsen, Ph.D.
- Phone Number: +4587165956
- Email: majajo@psy.au.dk
Study Locations
-
-
Jylland
-
Aarhus, Jylland, Denmark, 8000
- Active, not recruiting
- Aarhus University
-
Aarhus, Jylland, Denmark, 8000
- Recruiting
- Dept of Oncology, Aarhus University Hospital
-
Contact:
- Ingeborg Farver-Vestergaard, PhD-fellow
- Phone Number: +4587166154
- Email: ifarver@psy.au.dk
-
Sub-Investigator:
- Ingeborg Farver-Vestergaard, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- >18 yrs. of age
- completed primary cancer treatment
- experiencing moderate to severe pain >4 (11-point NRS)
Exclusion Criteria:
- incomplete chemotherapy or radiation therapy
- serious psychiatric diagnoses eg. psychosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MBCT
As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants.
The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
|
The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home.
The participants will be asked to record their home training to allow assessment of their adherence to the intervention.
Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session.
The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity assessed by NRS
Time Frame: Change in pain intensity from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain intensity during the last week is assessed by a 11-point numeric rating scale (NRS), range 0-10.
(0=no pain, 10= worst pain ever).
|
Change in pain intensity from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain interference assessed by NRS
Time Frame: Change in pain interference from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain interference with daily activities during the last week is assessed by a 11-point numeric rating scale (NRS), range 0-10.
(0=no interference, 10=maximal interference).
|
Change in pain interference from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain quality assessed by the McGill Pain Questionnaire (SF-MPQ-2)
Time Frame: Change in pain quality from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain quality is assessed by the McGill Pain Questionnaire, which consists of 22 items representing different descriptors of pain.
Each item is rated based on a 0-10 scale (0=no pain, 10=worst pain ever) during the last week.
The questionnaire comprises of four parts, including continuous, intermittent, neuropathic and affective pain.
|
Change in pain quality from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain burden assessed by NRS
Time Frame: Change in pain burden from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain burden is assessed by a 11-point numeric rating scale (NRS), range 0-10 "How burdensome have your pain been during the last week" (0=not burdensome, 10=very burdensome).
|
Change in pain burden from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Cancer-related quality of life assessed by EORTC-QLQ-C30
Time Frame: Change in cancer-related quality of life from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Cancer-related quality of life is assessed with the European Organisation for Research and Treatment of Cancer's quality of life questionnaire (EORTC-QLQ-C30), which consists of 30 items.
|
Change in cancer-related quality of life from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Health-related quality of life assessed by the EQ-5D-3L
Time Frame: Change in health-related quality of life from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Health-realted quality of life is assessed by the EQ-5D, which consists of 5 items, measuring five dimensions of health status: mobility, self-case, usual activities, apin/discomfort, anxiety/depression.
Each item is rated by marking a statement representing values at three levels 1-3.
Higher scores indicate lower levels of quality of life.
|
Change in health-related quality of life from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Well-being assessed by the WHO-5
Time Frame: Change in well-being from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Well-being is assessed by the World Health Organization Well-Being Index (WHO-5), which consists of 5 items.
Each item is rated on a 6-point Likert scale, ranging from 0-5.
Higher scores indicate higher levels of well-being.
|
Change in well-being from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Fear of cancer recurrence assessed by the FCRI-SF
Time Frame: Change in fear of cancer recurrence from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Fear of cancer recurrence is assessed with the Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF), which consists of 9 items.
Each item is rated on a 5-point Likert scale, ranging from 0-4.
Higher scores indicate higher levels of fear of cancer recurrence.
|
Change in fear of cancer recurrence from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Symptoms of depression assessed by the BDI
Time Frame: Change in depression symptoms from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Depressive symptoms are assessed by the Beck Depression Index (BDI), which consists of 21 items.
Each item is rated by marking a statement representing values from 0-3.
Higher scores indicate higher levels of depression symptoms.
|
Change in depression symptoms from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Sleep quality assessed by the ISI
Time Frame: Change in sleep quality from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Sleep difficulties are assessed by the Insomnia Severity Index (ISI), which consists of 7 items.
Each item is rated on a 5-point Likert scale, ranging from 0-4.
Higher scores indicate higher severity of insomnia.
|
Change in sleep quality from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain catastrophizing assessed by the PCS
Time Frame: Session-by-session change in pain catastrophizing from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Pain catastrophizing is assessed by the Pain Catastrophizing Scale (PCS), which consists of 13 items.
Each item is rated on a 5-point Likert scale (0=not at all, 4=all the time).
Higher scores indicate higher levels of pain catastrophizing.
|
Session-by-session change in pain catastrophizing from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Experiential avoidance assessed by the BEAQ
Time Frame: Session-by-sessions change in experiential avoidance from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Experiential avoidance is assessed by the Brief Experiential Avoidance Questionnaire (BEAQ), which consists of 15 items.
Each item is rated on a 6-point Likert scale, ranging from 1=strongly disagreee to 6=strongly agree.
Higher scores indicate higher levels of experiential avoidance.
|
Session-by-sessions change in experiential avoidance from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Mindfulness assessed by the FFMQ
Time Frame: Session-by-session change in mindfulness from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Mindfulness is assessed by the Five Facet Mindfulness Questionnaire (FFMQ), which consists of 39 items.
The questionnaire measures five mindfulness facets: acting with awareness, describing, nonjudging of inner experience, nonreactivity to inner experience, observing.
Each item is rated on a 5-point Likert scale (1=never or rarely true, 5=very often or always true).
Higher scores indicate higher levels of mindfulness.
|
Session-by-session change in mindfulness from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Self-compassion assessed by the SCS
Time Frame: Session-by-session change in self-compassion from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Self-compassion is assessed by The Self-Compassion Scale - Short form (SCS-SF), which consists of 12 items.
Each item is rated on a 5-point Likert scale (1=almost never, 5=almost always).
Higher scores indicate higher levels of self-compassion.
|
Session-by-session change in self-compassion from baseline (day 0) to post-intervention (up to 30 weeks after baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Zachariae, DMSCi, University of Aarhus
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2018
Primary Completion (Anticipated)
December 30, 2019
Study Completion (Anticipated)
March 1, 2020
Study Registration Dates
First Submitted
March 26, 2018
First Submitted That Met QC Criteria
July 6, 2018
First Posted (Actual)
July 19, 2018
Study Record Updates
Last Update Posted (Actual)
May 28, 2019
Last Update Submitted That Met QC Criteria
May 24, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MBCT-late effects 2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain Management
-
Assiut UniversityNot yet recruitingPain Management | Neonates Pain Management
-
Wolfson Medical CenterUnknownPain Management | Post Surgical Management | Inflamation ManagementIsrael
-
Sintetica SACross S.A.CompletedPhase 1: Pain Management | Phase 2: Pain ManagementSwitzerland
-
Värmland County Council, SwedenSykehuset Telemark; Örebro University, Sweden; Dalarna County Council, Sweden; Region... and other collaboratorsCompletedInfant Pain Management | Parent-driven Pain ManagementSweden
-
Cedars-Sinai Medical CenterCompletedImmersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled TrialPain | Pain ManagementUnited States
-
VA Office of Research and DevelopmentCompleted
-
Uludag UniversityRecruiting
-
The University of Texas Health Science Center at...Recruiting
-
Carilion ClinicChorda Pharma, Inc.Completed
-
Parkland Health and Hospital SystemCompletedPain ManagementUnited States
Clinical Trials on Mindfulness-Based Cognitive Therapy
-
University of WarsawNot yet recruitingModerate Depressive Episode | Mild Depressive Episode
-
Oregon Health and Science UniversityTerminatedPostpartum Depression | Prenatal Stress | Maternal Psychological DistressUnited States
-
The University of QueenslandUniversity of Alabama at Birmingham; Rush University Medical Center; University...Completed
-
Oregon Health and Science UniversityCompletedPregnancy Related | Infant Development | Prenatal Stress | Functional Neuroimaging | Maternal Psychological DistressUnited States
-
University of WashingtonNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
Vancouver Coastal HealthRecruitingSituational Erectile DysfunctionCanada
-
Massachusetts General HospitalMayo Clinic; University of Pennsylvania; University of South Florida; University... and other collaboratorsCompleted
-
University of California, Los AngelesCompletedMood Disorders | Bipolar Disorder | Parents | Prodromal Symptoms | Clinical High RiskUnited States
-
Qazvin University Of Medical SciencesUnknownInsomniaIran, Islamic Republic of
-
University Medical Center GroningenUniversity of GroningenCompleted